This Stanford study asks whether resident skeletal stem cells (SSCs) can be redirected after microfracture surgery to produce true articular cartilage instead of fibrocartilage. Using mouse OA models and a human fetal xenograft system, it tests whether targeted co-delivery of BMP2 and a VEGF antagonist can override the default fibrocartilage outcome.
Microfracture has been the workhorse marrow-stimulation technique since the 1950s, but its fibrocartilage regenerate is mechanically inferior to native articular cartilage and degrades over time — and until now, the cellular mechanism behind this failure was poorly understood.
This paper explains why: microfracture activates resident SSCs but deposits them into an environment that defaults to fibroblastic and osteogenic fates, not chondrogenesis. The actionable finding is the two-signal fix: microfracture to activate the SSC pool, then BMP2+sVEGFR1 co-delivery to redirect those cells toward stable hyaline-like cartilage.
When you perform microfracture for a chondral defect, the fibrocartilage outcome is not a surgical failure. It reflects SSC biology in an unmanipulated niche. Augmenting the procedure with VEGF blockade alongside BMP2 is the proposed lever to change that outcome.
Both agents have FDA-approved clinical versions (Infuse and Avastin), making this a realistic near-term translational target, though human clinical trial data in adult OA joints are still needed.
This Stanford study asks whether resident skeletal stem cells (SSCs) can be redirected after microfracture surgery to produce true articular cartilage instead of fibrocartilage. Using mouse OA models and a human fetal xenograft system, it tests whether targeted co-delivery of BMP2 and a VEGF antagonist can override the default fibrocartilage outcome.
Microfracture has been the workhorse marrow-stimulation technique since the 1950s, but its fibrocartilage regenerate is mechanically inferior to native articular cartilage and degrades over time — and until now, the cellular mechanism behind this failure was poorly understood.
This paper explains why: microfracture activates resident SSCs but deposits them into an environment that defaults to fibroblastic and osteogenic fates, not chondrogenesis. The actionable finding is the two-signal fix: microfracture to activate the SSC pool, then BMP2+sVEGFR1 co-delivery to redirect those cells toward stable hyaline-like cartilage.
When you perform microfracture for a chondral defect, the fibrocartilage outcome is not a surgical failure. It reflects SSC biology in an unmanipulated niche. Augmenting the procedure with VEGF blockade alongside BMP2 is the proposed lever to change that outcome.
Both agents have FDA-approved clinical versions (Infuse and Avastin), making this a realistic near-term translational target, though human clinical trial data in adult OA joints are still needed.